Leading Physicians to Unveil New Findings Regarding Arterial Calcification at TCT Conference

Leading Physicians to Unveil New Findings Regarding Arterial Calcification at TCT Conference

Investor Relations, 651-259-2800orSarah Wozniak, 651-259-1636orMatt Sullivan, 612-455-1709orDave Folkens, 612-455-1741

Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), announced today that new findings regarding arterial calcification will be unveiled at the 2012 Transcatheter Cardiovascular Therapeutics (TCT) conference in Miami, Oct. 22–26, 2012. Arterial calcification is a common, underdiagnosed condition and complicating factor for physicians treating peripheral arterial disease (PAD). It is estimated to be present in approximately 65 percent of the people treated annually for PAD.

CSI has also commenced its ORBIT II Investigational Device Exemption clinical trial to evaluate the safety and effectiveness of its orbital technology in treating coronary arteries. The coronary system is limited by federal law to investigational use and is currently not commercially available in the United States. Coronary arterial disease (CAD) is estimated to be present in approximately 38 percent of the people treated annually for CAD.

“Calcified Lesions: New Insights in Stable CAD and acute coronary syndrome (ACS) from Large-Scale Clinical Trials”, presented by Dr. Philippe Généreux; and “Decalcification with the Orbital Atherectomy System: Case Presentation” (with discussion), presented by Dr. Jeffrey Chambers.

Monday, Oct. 22, 12:37 – 12:57 p.m.

Miami Beach Convention Center, Hall A

Two evening sessions will explore the historical challenge of coronary calcification and emerging technologies for peripheral interventions.

“The Challenge of Coronary Calcification: From Yesterday to Tomorrow”, moderated by Dr. Gregg Stone and Dr. Gary Mintz

Tuesday, Oct. 23, 6:30 – 8:45 p.m.

Ritz Carlton South Beach Hotel, Salons 1-2

“Emerging Technologies for Peripheral Interventions: Device Selection, Technical Approach and Clinical Outcomes”, presented by Dr. Juan Granada and Dr. Barry Katzen

Thursday, Oct. 25, 6:30 – 8:45 p.m.

Loews Miami Beach Hotel, Americana Ballroom, Salon 4

Dr. Jeffrey Chambers will conduct a live presentation of his ORBIT II case as part of the Coronary Interventions taped cases session. (See ORBIT II description below)

Oct. 25, 4:30 – 5:00 p.m.

Miami Beach Convention Center, Presentation Theater 1

–Visit CSI at booth #926, noon – 5 p.m., Tuesday, Oct. 23, and 9 a.m. – 5 p.m. Wednesday, Oct. 24 and Thursday, Oct. 25.

PAD is a life-threatening condition where a fatty material called plaque builds up on the inside walls of the blood vessels that carry blood from the heart to legs and arms. The plaque buildup causes the arteries to harden and narrow (atherosclerosis), reducing blood flow to the legs. The risk of PAD increases if a person has one or several of the following: high blood pressure, abnormal cholesterol levels, diabetes, or personal history of heart disease, heart attack or stroke. PAD affects an estimated 8-12 million people in the United States. The disease prevalence increases with age and 12-20 percent of Americans age 65 and older suffer from PAD symptoms. As the U.S. population ages, the prevalence range could reach 16 million in those age 65 and older and 19 million overall by 2050.

Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device company focused on developing and commercializing innovative solutions for treating vascular and coronary disease. The company’s Orbital Atherectomy Systems treat calcified and fibrotic plaque in arterial vessels throughout the leg in a few minutes of treatment time, and addresses many of the limitations associated with existing surgical, catheter and pharmacological treatment alternatives. The U.S. FDA granted 510(k) clearance for the use of the Diamondback Orbital Atherectomy System in August 2007. To date, nearly 100,000 of CSI’s devices have been sold to leading institutions across the United States. CSI has also commenced its ORBIT II Investigational Device Exemption clinical trial to evaluate the safety and effectiveness of its orbital technology in treating coronary arteries.

For more information, visit the company’s website at .

Suggested Articles

The Pharma Lions shortlist for 2019 lives up to its name with just 31 entries making the cut. But it's still good news for the 12 drugmaker finalists.

Pharma companies filed suit Friday to block the new HHS rule that requires drugmakers to put list prices in TV ads.

Cannes Lions Health kicks off Monday, and attendees are looking for some breakouts—leading-edge tech, creativity and inspiration, for instance.